Thus, since MPS1 has a role in both the AKT/mTOR pathway and in the activation of Aurora B activity, we believe that a combinatorial approach targeting EGFR and MPS1 could lead to an enhanced antiproliferative effect and increased cell death, and also prevent or overcome resistance to EGFR inhibition therapy in HNSCC. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.